Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Am J Med Sci ; 367(1): 4-13, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37832917

ABSTRACT

The rising prevalence of comorbidities in an increasingly aging population has sparked a reciprocal rise in polypharmacy. Patients with chronic kidney disease (CKD) have a greater burden of polypharmacy due to the comorbidities and complications associated with their disease. Polypharmacy in CKD patients has been linked to myriad direct and indirect costs for patients and the society at large. Pharmacists are uniquely positioned within the healthcare team to streamline polypharmacy management in the setting of CKD. In this article, we review the landscape of polypharmacy and examine its impacts through the lens of the ECHO model of Economic, Clinical, and Humanistic Outcomes. We also present strategies for healthcare teams to improve polypharmacy care through comprehensive medication management process that includes medication reconciliation during transitions of care, medication therapy management, and deprescribing. These pharmacist-led interventions have the potential to mitigate adverse outcomes associated with polypharmacy in CKD.


Subject(s)
Pharmacy , Renal Insufficiency, Chronic , Humans , Aged , Polypharmacy , Renal Insufficiency, Chronic/drug therapy , Pharmacists , Outcome Assessment, Health Care , Inappropriate Prescribing/prevention & control
2.
Nutrients ; 13(12)2021 Nov 24.
Article in English | MEDLINE | ID: mdl-34959763

ABSTRACT

The role of magnesium in blood pressure has been studied among hypertensive patients; however, there is a dearth of studies exploring the role of magnesium in hypertensive crises. The primary objective of this study was to evaluate the relationship between serum magnesium and blood pressure in patients with hypertensive crises. This was a single-center, retrospective, chart review, cross-sectional study of patients with hypertensive crises. Patients were included if they were eighteen years of age or older, with an international classification disease ninth revision (ICD-9) code of 401.9 (hypertensive crises: emergency or urgency) and a documented magnesium level on their electronic medical record. The primary outcome of the study was the correlation between serum magnesium and blood pressure (systolic blood pressure and diastolic blood pressure) in patients with hypertensive crises. Two hundred and ninety-three patients were included in the study. The primary outcome result showed that serum magnesium was positively correlated with systolic blood pressure (r = 0.143, p = 0.014), but not diastolic blood pressure. Conclusion: This study found a significant positive association between magnesium and systolic blood pressure, but not diastolic blood pressure, among patients with hypertensive crises. This positive association of serum magnesium with systolic blood pressure was maintained after adjusting for covariates. This study's findings suggest a potential role of magnesium in blood pressure among patients with hypertensive crises.


Subject(s)
Blood Pressure/drug effects , Hypertension/blood , Magnesium/blood , Adult , Aged , Aged, 80 and over , Cross-Sectional Studies , Diastole/drug effects , Female , Humans , Male , Middle Aged , Retrospective Studies , Systole/drug effects , Young Adult
3.
Educ Health (Abingdon) ; 34(2): 77-79, 2021.
Article in English | MEDLINE | ID: mdl-34937302

ABSTRACT

Background: Due to the unprecedented COVID-19 pandemic, learning institutions were faced with many challenges while transitioning their in-person courses to an online format for teaching, learning, and testing. One of these challenges included the continuation of assessments in a safe but secure manner. Discussion: Professional health programs may need to implement new policies to ensure a fair, safe testing process that maintains exam integrity during remote assessments. We concluded that transitioning to remote assessments for health professional schools posed many challenges. Further studies may elaborate the effectiveness and limitations of the various approaches used for remote assessments by professional health programs during the pandemic.


Subject(s)
COVID-19 , Pandemics , Health Personnel , Humans , Learning , Pandemics/prevention & control , SARS-CoV-2
4.
Hosp Pharm ; 56(5): 486-494, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34720150

ABSTRACT

Background: Amantadine has been used off-label to improve alertness after traumatic brain injury (TBI). The goal of this study is to assess the mean change at 72 hours and in course of therapy (COT) Glasgow Coma Scale (GCS) score after amantadine initiation and to correlate the change in GCS score with participation in physical therapy (PT) and occupational therapy (OT) among patients with TBI receiving amantadine during the first hospitalization. Methods: This single-center, retrospective, cohort study included patients ≥18 years old hospitalized for a TBI from August 2012 to February 2018 and received ≥1 dose of amantadine to increase alertness. The primary endpoint is the mean change in 72-hour GCS score after amantadine initiation. The secondary endpoint is the mean change in COT GCS score after amantadine initiation and the correlation between the change in GCS score and percent PT and OT participation at 72 hours and during the COT. Results: Seventy-nine patients were included. The mean age of patients was 41 years, and 79.8% of the patients were men. The mean change in 72-hour GCS score was +0.75 (95% confidence interval [CI] = 0.09-1.42, P = .027), and the mean change in COT GCS score was +2.29 (95% CI = 1.68-2.90, P < .001). There was no significant correlation between the increase in GCS score and percent PT/OT session participation at 72 hours and during the COT, r = -0.15 (P = .24) and r = -0.02 (P = .74), respectively. The percent PT/OT session participation at 72-hour post-amantadine initiation was 61.3% compared with 65.9% during the COT. Conclusion: There were small but statistically significant increases in the mean change at 72 hours and in COT GCS score; however, they were not correlated with percent PT/OT participation. Other studies are needed to determine the appropriate time and GCS score to initiate amantadine along with the optimal dose in the inpatient setting.

5.
J Clin Hypertens (Greenwich) ; 23(6): 1229-1238, 2021 06.
Article in English | MEDLINE | ID: mdl-33963802

ABSTRACT

Although the role of magnesium in blood pressure has been well studied among hypertensive patients, no study has explored the role of magnesium in hypertensive crises. The primary objective of this study is to evaluate the differences in serum magnesium levels between hypertensive crises patients and matched controls (age-, sex-, race-, and diabetes-matched) in a 1:1 random match. This study is a single-center, retrospective, chart review, case-control study of patients with hypertensive crises (case group) and patients without hypertensive crises (control group). Patients were included in the case group if they were 18 years of age or older with hypertensive crises and have a documented magnesium level. The control group patients were required to be 18 years of age or older, have no diagnosis of hypertensive crises, and have a documented magnesium level. The primary outcome of the study was to compare the mean serum magnesium in patients with hypertensive crises versus patients without hypertensive crises. Three hundred and fifty-eight patients were included in the study: 179 patients in both the case group and control group. The primary outcome results showed that serum magnesium concentration was not significantly different between the case group (1.89 ± 0.29 mg/dl) and control group (1.90 ± 0.31 mg/dl) (p = .787). This study found no significant difference in serum magnesium levels in patients with hypertensive crises compared to a random matched control group. Larger observational or experimental studies may be useful to evaluate the effect of magnesium on blood pressure in hypertensive crises.


Subject(s)
Hypertension , Magnesium , Adolescent , Adult , Blood Pressure , Case-Control Studies , Humans , Hypertension/drug therapy , Hypertension/epidemiology , Retrospective Studies
6.
Int J Clin Pract ; 74(7): e13504, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32243645

ABSTRACT

PURPOSE: The purpose of this study is to assess the effectiveness of mono antiplatelet therapy vs dual antiplatelet therapy in reducing recurrent stroke and mortality in patients with ischemic stroke or transient ischemic attack (TIA). A subgroup analysis was conducted to compare outcomes in African-American patients compared with non-African-American patients. METHODS: This is a single-centre, retrospective, chart review, cohort study conducted at the University Medical Center New Orleans (UMCNO), New Orleans, Louisiana. This study includes all patients who are admitted to UMCNO with a diagnosis of ischemic stroke or TIA. The subjects were divided into two groups, patients who received mono antiplatelet therapy and patients who received dual antiplatelet therapy. RESULTS: A total of 762 stroke patients were included in the study. Of these, 499 (65.5%) received mono antiplatelet therapy and 263 (34.5%) patients received dual antiplatelet therapy. There was no statistical significant difference in the incidence of mortality and recurrent stroke in the mono antiplatelet therapy group compared with the dual antiplatelet therapy group. When comparing primary outcomes between African Americans and non-African Americans, there was no statistical significant difference in mortality rate and recurrent stroke rate between the two groups. CONCLUSION: This study found no statistical significant difference in the incidence of recurrent stroke and mortality between mono antiplatelet therapy and dual antiplatelet therapy among patients who had ischemic stroke or TIA; with similar findings in a subgroup analysis comparing outcomes in African-American patients compared with non-African-American patients.


Subject(s)
Black or African American/statistics & numerical data , Brain Ischemia/drug therapy , Dual Anti-Platelet Therapy/methods , Ischemic Attack, Transient/drug therapy , Platelet Aggregation Inhibitors/therapeutic use , Secondary Prevention/methods , Cohort Studies , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Retrospective Studies , Stroke/therapy
7.
Innov Clin Neurosci ; 15(3-4): 17-23, 2018 Apr 01.
Article in English | MEDLINE | ID: mdl-29707422

ABSTRACT

Objective: The authors sought to assess the literature evidence on the efficacy of modafinil use in patients with fatigue or excessive daytime sleepiness (EDS) secondary to traumatic brain injury (TBI). Method of Research: A literature search of Medline and PubMed was performed using the EBSCOhost database. Primary literature, observational studies, meta-analyses, case reports, and systematic reviews were assessed for content regarding modafinil and psychostimulant use in patients with TBI. Of the 23 articles collected, three randomized, controlled studies, three observational studies, one case report, and two systematic reviews gave a description of modafinil use in TBI patients. Results and Conclusion: Modafinil is a central nervous system stimulant with well-established effectiveness in the treatment of narcolepsy and shift-work sleep disorder. There is conflicting evidence about the benefits of modafinil in the treatment of fatigue and EDS secondary to TBI. One randomized, controlled study states that modafinil does not significantly improve patient wakefulness, while another concludes that modafinil corrects EDS but not fatigue. An observational study provides evidence that modafinil increases alertness in fatigued patients with past medical history of brainstem diencephalic stroke or multiple sclerosis. Modafinil appears to have the potential to improve wakefulness in patients with TBI. A prospective, double-blinded, randomized, crossover trial of modafinil for the management of fatigue in ischemic stroke patients is currently being conducted, and further studies demonstrating consistent results are needed before making a conclusive decision.

8.
Article in English | MEDLINE | ID: mdl-28956852

ABSTRACT

Cigarette smoking-a crucial modifiable risk factor for organ system diseases and cancer-remains prevalent in the United States and globally. In this literature review, we aim to summarize the epidemiology of cigarette smoking and tobacco use in the United States, pharmacology of nicotine-the active constituent of tobacco, and health consequence of cigarette smoking. This article also reviews behavioral and pharmacologic interventions for cigarette smokers and provides cost estimates for approved pharmacologic interventions in the United States. A literature search was conducted on Google Scholar, EBSCOhost, ClinicalKey, and PubMed databases using the following headings in combination or separately: cigarette smoking, tobacco smoking, epidemiology in the United States, health consequences of cigarette smoking, pharmacologic therapy for cigarette smoking, and non-pharmacologic therapy for cigarette smoking. This review found that efficacious non-pharmacologic interventions and pharmacologic therapy are available for cessation of cigarette smoking. Given the availability of efficacious interventions for cigarette smoking cessation, concerted efforts should be made by healthcare providers and public health professionals to promote smoking cessation as a valuable approach for reducing non-smokers' exposure to environmental tobacco smoke.


Subject(s)
Cigarette Smoking/adverse effects , Tobacco Use Cessation , Humans , Nicotine , Prevalence , United States
9.
Am J Pharm Educ ; 73(1): 5, 2009 Feb 19.
Article in English | MEDLINE | ID: mdl-19513142

ABSTRACT

OBJECTIVES: To assess the effectiveness, efficiency, and student satisfaction with computer-mediated instruction (CMI) versus lecture-mediated instruction (LMI) of pain management to doctor of pharmacy (PharmD) students. METHODS: This study compared the instruction of pain management by CMI versus LMI. An examination was administered and a student survey was conducted to determine effectiveness and student perception of efficiency and satisfaction with these teaching methods. RESULTS: Mean examination scores were not significantly different between the 2 groups, with 62 (91%) of the LMI group and 46 (94%) of the CMI group scoring > or =70% (p = 0.73). Efficiency and student perception of learning significantly increased in the CMI group. CONCLUSIONS: CMI appears to be at least as effective as LMI in teaching pain management to pharmacy students and students perceive that efficiency and learning is increased with CMI. Therefore, CMI seems to be a viable teaching option.


Subject(s)
Computer-Assisted Instruction/methods , Education, Pharmacy/methods , Students, Pharmacy/psychology , Data Collection , Educational Measurement , Humans , Pain Management , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...